International Conference & B2B on Pharma Research and Development June 06-07, 2018 Philadelphia, Pennsylvania, USA

Refaat M. Mahfouz is now a professor of materials sciences at the department of chemistry , Faculty of science , Assiut university , Egypt. He holds his B.Sc. , M.Sc., and Ph.D., degrees from Assiut university , Egypt . He got more than one fellowship to work as a guest scientist at nuclear research Centre , juelich , and nuclear research Centre , Dresden , Germany .He was a guest scientist for two weeks at Cosmo chemistry institute , university of Hawaii , USA in 2010 He shifted to work as a prof. of materials sciences and nuclear sciences at King Saud University , Saudi Arabia in the period from 1996-2011. He has published more than one hundred publications in the field of nuclear chemistry ,radiation chemistry ,bio-inorganic chemistry, solid state chemistry ,and nanotechnology in ISI scientific journals such as Radiochimica Acta , Radioanalytical and Nuclear chemistry Articles , Radiation Effects and Defects in Solids , Radiation Physics and Chemistry , Thermochimica Acta and others. He has one Patent in nanotechnology. He supervised more than 20 theses in the field of solid state chemistry, nanotechnology and radiochemistry ,He translated the book “ Basic Solid State Chemistry” by Antony West , The book “ Crystal Structure Analysis Principles and Practice by W. Clegg and et al.. to Arabic language. He has good experience in X-ray single crystal analysis and he has publications in this field in ISI International crystallographic journals. In addition to this he has also good experience in computational chemistry and he has some publications in this field. He serves as a reviewer in a wide range of international journals.

solid state chemistry, nanotechnology and radiochemistry, nuclear chemistry ,radiation chemistry ,bio-inorganic chemistry.

Stephen J. Fey has a background in biomedical science having worked in research universities and companies for the past 30 years. He obtained his PhD at Kings College, London University. He became a pioneer in 2D gel electrophoresis using 2DGE to study cervical cancer, diabetes and cardiovascular problems. SJF has 116 publications in peer-reviewed scientific journals and has filed 34 patents. He was the co-founder of the Centre for Proteome Analysis in 1997 (a new institute at the University of Southern Denmark & the world’s first purpose built proteomics institute) and became CEO when the institute was spun out of the SDU to become DrugMode ApS in 2006. In 2011 he became TCEL group leader at SDU, developing 3D cell and tissue culture systems to mimic in vivo physiology and toxicology. He was co-founder of CelVivo in 2014, a spin out company, commercialising equipment and disposables for 3D cell culture.

Developing 3D cell and tissue culture systems to mimic in vivo physiology and toxicology.

Carmen Tamayo, MD directs the Canada Region of HeteroGeneity, LLC. Venezuelan by birth and Canadian by citizenship, she trained in internal medicine at the Central University of Venezuela. After moving to Canada with family, she completed postgraduate studies in Public Health and Epidemiology at the University of Toronto. Since 1995, she has actively participated in policy and regulatory activities addressing traditional, complementary and alternative medicine (TCAM) research, with the Canadian National Cancer Institute. Her consulting has included government, industry, and nonprofit scientific organizations, including HeteroGeneity (since 2008), McMaster University Centre for Evidence Based Medicine, and the University of Western Ontario School of Medicine and Dentistry at the University of Western Ontario. For Health Canada’s Natural Health Products (NHP) Directorate she served as Clinical Trial Project Coordinator for Product Review and Assessment, collaborating in the Agency’s development of a framework for NHP clinical trials. She has chaired and directed numerous programs and workshops as a member of the Drug Information Association (DIA), The International Pharmaceutical Federation (FIP), and the Latin American phytomedicine society (Sociedad Latinoamericana de Fitomedicina). She also serves as an expert reviewer for the World Health Organization and other international committees and several CAM and Phytotherapy journals, and is a past co-editor of the Journal of Integrative and Complementary Medicine (JICM) – An international forum for evidence-based practices.

Clinical Trials

Freddie Ann Hoffman, MD founded HeteroGeneity in 2003, a Washington, DC-based consultancy focused on complex natural products, and is also its Managing Member. She has over 35 years of product development experience. She has a BS in Chemistry from UCLA and received her MD and general pediatric residency training from the University of California at Davis. She completed a fellowship in pediatric hematology-oncology at the National Cancer Institute (NCI), staying on to direct the Nutrition and Supportive Care Section of the Division of Cancer Treatment, and later, as Director of Extramural Clinical Trials of the Biological Response Modifiers Program. Leaving NCI in 1986, she served at FDA for nearly 14 years, as Chief of the Cytokines, Growth Factors and Oncologic Products Branch of the Center for Biologics Evaluation and Research, and later as Deputy Director of the Medicine Staff in the Office of the Commissioner. During her tenure, she formed and chaired an internal FDA Botanical Working Group which developed the Botanical Drug guidance, which the Agency finalized in 2004. She also served in the Office of Dietary Supplements at the Center for Food Safety and Applied Nutrition, before moving to the private sector in 1999, joining Warner-Lambert Pfizer Consumer Healthcare, where she was Senior Medical Director for New Product Development. Dr. Hoffman continues to serve on numerous working groups, task forces, and boards of both government agencies and private companies. She has chaired and participated in numerous scientific, regulatory and policy forums, addressing the development of polymolecular drugs and complex product development. In 2014, she was an invited speaker at the 18th Presidential Commission on Bioethics (BRAIN initiative). She is a member of the American Society of Pharmacognosy and a past chair of the Drug Information Association’s Natural Health Products Track.

Clinical Trials

Freddie Ann Hoffman, MD founded HeteroGeneity in 2003, a Washington, DC-based consultancy focused on complex natural products, and is also its Managing Member. She has over 35 years of product development experience. She has a BS in Chemistry from UCLA and received her MD and general pediatric residency training from the University of California at Davis. She completed a fellowship in pediatric hematology-oncology at the National Cancer Institute (NCI), staying on to direct the Nutrition and Supportive Care Section of the Division of Cancer Treatment, and later, as Director of Extramural Clinical Trials of the Biological Response Modifiers Program. Leaving NCI in 1986, she served at FDA for nearly 14 years, as Chief of the Cytokines, Growth Factors and Oncologic Products Branch of the Center for Biologics Evaluation and Research, and later as Deputy Director of the Medicine Staff in the Office of the Commissioner. During her tenure, she formed and chaired an internal FDA Botanical Working Group which developed the Botanical Drug guidance, which the Agency finalized in 2004. She also served in the Office of Dietary Supplements at the Center for Food Safety and Applied Nutrition, before moving to the private sector in 1999, joining Warner-Lambert Pfizer Consumer Healthcare, where she was Senior Medical Director for New Product Development. Dr. Hoffman continues to serve on numerous working groups, task forces, and boards of both government agencies and private companies. She has chaired and participated in numerous scientific, regulatory and policy forums, addressing the development of polymolecular drugs and complex product development. In 2014, she was an invited speaker at the 18th Presidential Commission on Bioethics (BRAIN initiative). She is a member of the American Society of Pharmacognosy and a past chair of the Drug Information Association’s Natural Health Products Track.

Clinical Trials

Sandro R. P. da Rocha, Professor in Pharmaceutics and Director for Pharmaceutical Engineering – School of Pharmacy, Chemical & Life Science Engineering and Massey Cancer Center My expertise is in the broad area of Nanomedicine. My long-term goal is to develop innovative drug and gene nanocarriers and engineer formulations for their pulmonary administration, for the treatment of local lung diseases and systemic disorders. We seek to achieve our objectives by engineering carriers with controlled morphology, size, and surface chemistry. Nanocarriers are of great relevance as they provide opportunities to mediate the interaction between the therapeutic molecules and the physiological environment so as to achieve not only spatially and temporally resolved release of drugs, but also to target the payload to specific tissues/cell populations/ intracellular organelles, while at the same time protecting the cargo from degradation. We study the interaction of nanocarriers at various biological interfaces, with particular focus to the lungs, including tissue, cell and organelle level, both in vitro and in vivo. My group uses a combined experimental and computational strategy to probe these interfaces.

Pharmaceutics and Chemical & Life Science Engineering

Hai-Feng Ji is currently working as a Professor, in Department of Chemistry, and Drexel University. His research interests focused on drug discovery, MEMS devices, nanomaterials for energy and environmental applications, nanopillars and phosphene for energy applications, and surface chemistry. He is currently a Co-author of 160 peer-viewed journal articles and book chapters. He has an H-index of 30. He is an Editorial board Member of several chemistry journals.

Drug Discovery

Michael Chorny is an Associate Professor in the Department of Pediatrics from University of Pennsylvania and the Children’s Hospital of Philadelphia (CHOP). He has received his Doctoral training in Pharmaceutical Sciences at the Hebrew University of Jerusalem and is pursuing his Post-doctoral studies at CHOP. In 2009, he joined the Faculty of Perelman School of Medicine at the University of Pennsylvania. His research focuses on development and evaluation of biodegradable nanocarriers for targeted delivery of drugs, gene vectors and cells for cardiovascular disease applications and cancer therapy.

Pharmaceutical Sciences

Gus R. Rosania is a Professor of Pharmceutical Sciences at the University of Michigan College of Pharmacy. Here, he leads a research group studying the transport mechanisms responsible for the disposition of small molecule drugs from the whole organism to the subcellular level. His research group has taken a special interest in studying poorly soluble drugs with very large volumes of distribution. His investigations combine physical, chemical, biological and computational studies with the ultimate goal of repurposing drugs by developing novel formulations for site directed drug targeting and delivery.

Pharmceutical Sciences